Nonclinical safety testing of imaging agents, contrast agents and radiopharmaceuticals
Author:
- 24 August 2020
- journal article
- review article
- Published by Wiley in Journal of Applied Toxicology
- Vol. 41 (1) , 95-104
Abstract
Drug development includes imaging agents, contrast agents and radiopharmaceuticals; these materials differ from therapeutic drugs in that they are largely used to diagnose and/or monitor diseases and not treat them. Consequently, nonclinical safety testing needs are different. An examination of testing packages supporting clinical entry and/or marketing of these materials has shown a common approach to some study types (eg, imaging, biodistribution and toxicity testing). Recent regulatory guidelines to support development are the United States Food and Drug Administration (FDA)’s “Guidance for Industry Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations” and the European Medicines Agency (EMA)’s “Guideline on the Non‐Clinical Requirements for Radiopharmaceuticals” (currently draft). It is hoped that these documents will allow developers to only perform nonclinical studies that are necessary to support functionality, follow distribution of the material and examine general safety/toxicity. However, as they are mainly focused on radiopharmaceuticals, companies are likely to apply knowledge of established testing packages to other new imaging agents and/or follow principles given in older regulatory guidelines, namely FDA’s “Guidance for Industry Developing Medical Imaging Drug and Biological Products Part I Conducting Safety Assessments”. Thus, in some cases, the need for regulatory agency interaction is still vital to avoid development surprises and delays due to an incomplete or badly performed testing package.Keywords
This publication has 9 references indexed in Scilit:
- Nonclinical Profile of BLZ-100, a Tumor-Targeting Fluorescent Imaging AgentInternational Journal of Toxicology, 2017
- Acute and subacute toxicity studies of CMICE-013, a novel iodinated rotenone-based myocardial perfusion tracer, in Sprague Dawley rats and Gottingen minipigsRegulatory Toxicology and Pharmacology, 2016
- Incorporation of safety pharmacology endpoints in the toxicological assessment of a potential diagnostic positron emission tomography (PET) imaging agentJournal of Pharmacological and Toxicological Methods, 2016
- Development, preclinical safety, formulation, and stability of clinical grade bevacizumab-800CW, a new near infrared fluorescent imaging agent for first in human useEuropean Journal of Pharmaceutics and Biopharmaceutics, 2016
- Non-clinical safety assessment of gadoterate meglumine (Dotarem®) in neonatal and juvenile ratsRegulatory Toxicology and Pharmacology, 2015
- Etiology of cecal and hepatic lesions in mice after administration of gas-carrier contrast agents used in ultrasound imaging☆Toxicology and Applied Pharmacology, 2003
- Preclinical studies of [99mTc]DTPA-mannosyl-dextran☆Nuclear Medicine and Biology, 2003
- Intestinal and hepatic lesions in mice, rats, and other laboratory animals after intravenous administration of gas-carrier contrast agents used in ultrasound imagingToxicology and Applied Pharmacology, 2003
- Biochemical and Morphological Effects of Contrast Media on the KidneyActa Radiologica, 1995